76 -4 (28/2) 2019 — Samadov B.S., Musaeva D.M., — COMPARATIVE CHARACTERISTICS AND TRENDS OF THE EPIDEMIC PROCESS OF HEPATITIS C IN UKRAINE AND UZBEKISTAN

COMPARATIVE CHARACTERISTICS AND TRENDS OF THE EPIDEMIC PROCESS OF HEPATITIS C IN UKRAINE AND UZBEKISTAN

Samadov B.S., Bukhara State Medical institute, National University of Pharmacy, Kharkiv, Ukraine.

Musaeva D.M., Bukhara State Medical institute, National University of Pharmacy, Kharkiv, Ukraine.

Dubinina N.V., Bukhara State Medical institute, National University of Pharmacy, Kharkiv, Ukraine.

Resume,

The regularities and current trends of the epidemic process of hepatitis C in Ukraine and Uzbekistan, especially its spread among different groups of the population. As the incidence of acute hepatitis C decreases, the number of people chronically infected with HCV increases. Set the leading way of transmission of infection: injecting drug use, sexual and in medical parenteral interventions. The high intensity of the hidden component of the epidemic process of hepatitis C.

Keyword: Hepatitis C, incidence, prevalence, epidemic process, transmission pathways, seroepidemiological studies.

First page

284

Last page

289

For citation: Samadov B.S., ‘Musaeva D.M., Dubinina N.V., Comparative characteristics and trends of the epidemic process of hepatitis c in Ukraine and Uzbekistan//New Day in Medicine 4(28)2019 284-289 https://cutt.ly/sbfu7gf

List of References

1. Batskix S.N. Bezinterferonovaya terapiya xronicheskogo gepatita S: smena preparatov Ili novaya paradigma lecheniya? // Rossiyskiy jurnal gastroenterologii, gepatologii, koloproktologii. 2014; 4: 23­31. (In Russ)
2. Bogomolov P.O., Dubinina N.V., Bueverov A.O. i Dr. Standartniy interferon-alfa pri 1-m genotipe virusa gepatita S: klinicheskoy i ekonomicheskiy analiz ego effektivnosti // Infeksionnie bolezni. 2013; 11(3): 8-14. (In Russ)
3. Virusnie gepatiti v Rossiyskoy Federatsii: Spravochnik / Pod red. G.G. Onishenko, A.B. Jebrunka. SPb. NIIEM im. Pastera, 2013. (In Russ)
4. Goryacheva L.G., Rogozina N.V., Mamaeva V.A., Ivanova V.V. Perinatalniy virusniy gepatit S i vozmojnosti ego lecheniya // Epidemiologiya i infeksionnie bolezni. 2014; 18(3): 4-8. (In Russ)
5. Shibne V.A., Mishin D.V., Garaev T.M. i Dr. Protivovirusnaya aktivnost ekstraktov griba Inonotus obliquus v otnoshenii infeksii, vizvannoy virusnoy gepatita S, v kulturax kletok // Byull. Eksp. Biologii i meditsini. – 2011; 151(5): 549-551. (In Russ)
6. Reddy K.R., Zeuzem S., Zoulim F. et al. Simepriver versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infectoin (ATTAIN a randomized, double blind, non­inferiority phase 3 trial // The Lancet. Infectious Diseases. 2014; 15: 27-35.
7. Rodriguez-Torres M., Lawitz E., Conway B. et al. Safety and antivirial activity of the HCV non-nucleoside polymerase inhibitor VX-222 treatment-nave genotype 1 HCV-infected patients // Hepatology. 2010; 52 (Supll. 1): 14.
8. Sanchez-Tapias J.M. Treatment of HCV genotype I nave patients with triple therapy: who, when and how long // Therapy liver diseases / Ed. By P. Giner, X. Forns, J.G. Abraldes. Barcelona: Elsevier Doyma, 2011. 23.
9. Zeuzem S., Buggiseh P., Agarwal K. et al. The protease inhibitor, tegobuvir alone, with ribavirin, or pegalated interferon plus ribavirin in hepatitis C // Hepatology. 2012; 55: 749-758.
10. Poordad F., McCone J.Jr., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection // N.Engl, J. Med. – 2011; 364(13): 1195-206.
11. Song H., Li J., Shi Sh., et al. Thermal stability and inactivation of hepatitis C virus grown in cell culture // Virol. J. – 2010; 7(40): 1-9.
12. Guevin C., Lamarre A., Labonte P. Novel HCV replication mouse model using human hepatocellular carcinoma xenografts // Antiviral Res. – 2009; 84(1): 14-22.
13. Nikolaeva L.I., Samoxodskaya L.M., Mashkova i Dr. Poisk geneticheskix faktorov virusa gepatita S i patsientov s xronicheskim gepatitom S, assotsiirovannix s formirovaniem ustoychivogo virusologicheskogo otveta na protivovirusnuyu terapiyu // V mire virusnix gepatitov. – 2011; 1: 26-35. (In Russ)
14. Deryabin P.G., Shaxgildyan I.V. Gepatit S: fundamentalnie i prikladnie porblemi // V sb.: Izuchenie evolutsii virusov v ramkax problem biobezopasnosti i sotsialno znachimix infeksiy / Red.: akademik RAMN D.K. Lvov, chlen-korrespondent RAMN L.V. Urivaev. – M., 2011; 89-98. (In Russ)
15. Deryabin P.G., Isaeva E.I., Maldov D.G., i Dr. Deystvie preparata stimforte na infeksiyu, vizvannuyu virusom gepatita S, genotip 1b // Voprosi virusologii. – 2009; 2: 17-20. (In Russ)
16. Gepatit S v Ukraine: epidemiologicheskie aspekti problemi / A.L. Gural, V.F. Marievskiy, T.A. Sergeeva [ta кд.] // SuchasnK KnfeksK^. – 2008; 1: 53-63. (In Russ)
17. Cause of death in individual with chronic HBV and/or HCV infection, a nationwide community-based register study / A.S. Duberg, A. Trner, L. Davisdttir [et al.] / J. Viral. Hepatol. – 2008; 15: 538-550.
18. Koziel M.J. Viral Hepatitis in HIV Infection / Margaret James Koziel, Marion G. Peters // N. Engl. J. Med. – 2007; 356(14): 1445-1454.